These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CXC chemokines, MIP-2 and KC, induce P-selectin-dependent neutrophil rolling and extravascular migration in vivo. Zhang XW, Liu Q, Wang Y, Thorlacius H. Br J Pharmacol; 2001 Jun; 133(3):413-21. PubMed ID: 11375258 [Abstract] [Full Text] [Related]
12. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation. Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD. Pulm Pharmacol Ther; 2015 Oct 01; 34():37-45. PubMed ID: 26271598 [Abstract] [Full Text] [Related]
20. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, Murdoch C. Int J Cancer; 2011 Aug 15; 129(4):847-58. PubMed ID: 21328342 [Abstract] [Full Text] [Related] Page: [Next] [New Search]